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Abstract
On 28th January 2004 patient P.T., aged 56, suffered an extensive and complicated anterola-
teral myocardial infarction with low output syndrome and double ventricular tachycardia
interrupted by electrical cardioversion. Emergency coronary angiography and percutaneous
coronary intervention of the left anterior descending artery with a result of 100%Æ5% and left
circumflex with a result of 99%Æ0% were performed with simultaneous implantation of stents
at the Royal Perth Hospital in Australia. The patient required intubation, intra-aortal
counterpulsatio, ECG assessment, blood pressure measurement and invasive haemodynamic
monitoring (CI, CO, PAWP, PAP). On the fifth day, in the face of lack of haemodynamic
improvement, an additional infusion of levosimendan was added to the infusion of noradrena-
lin and dobutamine, which resulted in a slight transient improvement in the clinical status of
the patient. In view of the unsatisfactory haemodynamic parameters and following a prelimi-
nary qualification for cardiac transplant (OHTx), a mechanical device supporting the function
of the left ventricle was implanted without complications into the abdominal cavity on the 30th
day of hospitalisation. On 15th April 2005 OHTx was performed with good clinical results.
(Folia Cardiol. 2006; 13: 524–529)
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Introduction
Artherosclerosis is the most frequent cause of
heart failure in Poland (75% cases) and in Western Eu-
rope, Northern America and Australia (50% of cases).
The condition leads to myocardial ischaemia [1, 2].
The growing number of patients with heart defects
results from the ageing of the population but is also
linked to pharmacotherapeutical development and
improvement in the survival of patients undergoing
immediate percutaneous coronary intervention (PCI)
in the course of acute coronary syndromes. Howev-
er, some of the patients saved by PCI go on to de-
velop congestive heart failure (CHF).
Cardiogenic shock is a complication of approx-
imately 10% of myocardial infarctions and consti-
tutes a major cause of death in acute coronary syn-
drome with ST-elevation myocardial infarction
(STEMI) [3]. Hospital mortality of patients with
STEMI and with fully symptomatic cardiogenic
shock is 70–90% and is not  significantly reduced
with the application of thrombolytic treatment [4].
Gruppo Italiano per lo Studio della Streptochinasi
nell’Infarto Miocardico (GISSI) study showed that
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mortality among patients with cardiogenic shock re-
ceiving intravenous streptokinase reached 70% [5].
The introduction into clinical practice of PCI as
a mode of treatment for STEMI patients has ena-
bled a significant improvement in prognosis to be
achieved, which has been expressed by a decrease
in hospital mortality from 78% to 46% [6]. In some
patients, despite mechanical restoration of paten-
cy of the artery responsible for the myocardial inf-
arction and restoration of a normal TIMI 3 flow,
heavy progressive dysfunction of the left ventricle
occurs.
The American Society of Cardiology puts the
number of new CHF cases at 400 000 per year [7].
Some of these patients may be saved only through
heart transplantation. An extreme form of coronary
disease and primary dilated cardiomyopathy are
currently the most frequent indications for heart
transplant, accounting for 46.1% and 45.3% of cas-
es respectively [8].
We present a description of a patient with STEMI
of the anterolateral wall complicated by cardiogen-
ic shock who was hospitalised at the Royal Perth
Hospital in Australia in 2004.
Case description
A 56-year-old Australian male with a positive
family history of premature atherosclerosis and who
had suffered an inferior myocardial infarction in
1995 was admitted to the Intensive Care Unit of the
Royal Perth Hospital on 28th January 2004 in the
fourth hour of anterolateral STEMI complicated
with cardiogenic shock, low output syndrome (LOS)
and double ventricular tachycardia interrupted by
electrical cardioversion during transfer to hospital.
On admission the patient was intubated, after which
continuous positive airway pressure (CPAP) had to
be applied for three days. In ECG pathological Q
waves were noticed in leads II, III and AVF and
3 mm ST elevation in leads V1–V6. Coronarography
performed 5 hours after the onset of retrosternal pain
revealed occlusion of the proximal left anterior de-
scending artery (LAD) in segment 6 and 99% nar-
rowing of the left circumflex (LCx) in segment 11.
PCI of LAD with a Boston Scientific Taxus 3.0/28
mm implantation stent with a result of 100% to 5%
(TIMI 2) and PCI of the LCx with a Boston Scien-
tific Taxus 3.0/20.0 mm stent with a result of 99%
to 0% were performed simultaneously. The following
were administered: aspirin in a preliminary dose of
300 mg and then 150 mg daily, abciximab — bolus
0.25 mg/kg 10 min before the start of intervention
followed by an infusion of 0.125 mg/kg/min for
12 hours, clopidogrel in a preliminary dose of 300 mg
then 75 mg daily and simvastatin at a dose of 40 mg
daily. The patient had intra-aortic balloon counter-
pulsation (IABP) support with 1:1 temporary 2:1
augmentation for the first 12 days of hospitalisation.
Heart rate monitoring and blood pressure measure-
ment were required. Haemodynamic parameters
such as cardiac output (CO), cardiac index (CI),
pulmonary artery wedge pressure (PAWP), and
pulmonary artery pressure (PAP) were measured
with a Swan-Ganz catheter. Immediately after PCI
the following results were obtained: CO amount-
ed to 4.4 l/min, CI: 2.5 l/min/m2, PAWP: 22 mm Hg
and PAP: 40 mm Hg. Echocardiography revealed
extensive anterolateral wall and interventricular
septum akinesis. Persistent foramen ovale was
excluded. Left ventricular ejection fraction (LVEF)
was 16%.
During the first four days of hospitalisation the
following were used in medication for LOS: dob-
utamine at a maximum dose of 10 mg/kg/min in as-
sociation with noradrenalin at a maximum daily dose
of 4 mg, furosemide, aldacton, ramipril and digoxin
(with the use of serum levels to guide digoxin dos-
ing). As there was no haemodynamic improvement
(CO: 4.4 l/min, CI: 2.1 l/min/m2, PAWP: 30 mm Hg,
PAP: 44 mm Hg), the patient was moved to the
Advanced Heart Failure and Cardiac Transplant
Service on the fifth day of hospitalisation and here
levosimendan was administered at a loading dose
of 6 mg/kg over 10 minutes and then at an infusion
rate of 0.1 mg/kg/min. If systolic blood pressure was
> 90 mm Hg after 1 hour, the dose was increased
to 0.2 mg/kg/min until finished. Levosimendan was
administered to the full dose of 12.5 mg, which
resulted in a transient improvement in clinical sta-
tus of the patient, expressed in decreased dyspnoea
and fatigue. Echocardiography, in contrast, revealed
left ventricular failure.
By the 30th day of hospitalisation, in view of
the unsatisfactory haemodynamic parameters (CO:
4.4 l/min, CI: 2.1 l/min/m2, PAWP: 38 mm Hg),
the patient qualified for control coronarography,
which showed a good result from PCI of LAD and
LCx. Indications for heart transplantation (OHTx)
were established and immediately after eligibili-
ty had been established a mechanical device sup-
porting the function of the left ventricle (LVAD),
HeartMate XVE (Thoratec), was implanted with-
out complications into the abdominal cavity, result-
ing in gradual haemodynamic improvement (CI:
3.17 l/min/m2, PAWP: 30 mm Hg, LVEF: 23%).
Figure 1 illustrates the HeartMate XVE implan-
tation.
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After LVAD implantation the application of
b-adrenolytics (carvedilol and next bisoprolol) was
possible in the therapy of heart failure. Embolic com-
plications (microembolia to the cerebral arteries) and
inflammatory complications (local infection of the post-
surgical wound) were observed but these were not
life-threatening. Staphylococcus aureus and Citro-
bacter Koseri were cultured on material taken from
the LVAD cannula. In targeted antibiotic therapy van-
comicine and ticarcillin with clavulanic acid i.v. were
used temporarily and flucloxacillin in intracardiac in-
fusion (PICC line) and moxfloxacin 400 mg per os.
In the case of the patient described by us LVAD
implantation was a bridge to heart transplantation.
On 15th April 2005, after a period of 13.5 months
with LVAD, OHTx was performed. The patient re-
mains in the care of the Cardiac Transplant Serv-
ice of the Royal Perth Hospital.
Discussion
Cardiogenic shock is a clinical condition in
which the critical decrease of cardiac output caused
by damage to the myocardium and disturbances in
the autoregulation of  the circulatory system cause
deep disruption of tissue metabolism, oxygen de-
mand and energy-bearing substrates and impair-
ment of metabolite elimination [9]. The most
frequent reason for cardiogenic shock is disturbance
of the myocardium structure and function during the
acute phase of infarction. On the basis of pathomor-
phological studies it has been found that the shock
develops when contractility irregularity caused by
heart infarction or ischaemia cover over 40% of the
left ventricle muscle weight [10]. The most fre-
quently accepted clinical criteria of cardiogenic
shock include systolic pressure below 80 mm Hg
and symptoms of circulatory hyperperfusion, includ-
ing cold marble-like skin and hourly diuresis below
20 ml/h. In haemodynamic assessment cardiogenic
shock is diagnosed when CI is below 1.8 l/min/m²,
PAWP is above 20 mm Hg and peripheral resist-
ance is over 25 Wood units [5, 10, 11, 12]. In the
majority of Polish hospitals diagnosis of cardiogen-
ic shock and LOS is based on clinical criteria. It
should be noted that in the Royal Perth Hospital
diagnosis of cardiogenic shock and LOS is based on
haemodynamic measurements: CO, CI, PAWP,
PAP. Prospects for survival and improvement in
cardiogenic shock complicating a massive heart in-
farction are linked to the temporary application of
mechanical circulatory support methods: intra-aor-
tic balloon pump contrapulsation (IABP), percuta-
neous cardiopulmonary support (PCS) and the Sys-
tem Nimbus Haemopump [13].
PCI with mechanical circulation support using
IABP was immediately applied. Because of the per-
sistent LOS the measures were continued for as
long as 12 days following the successful coronary
intervention. An additional advantage of the treat-
ment applied, along improvement in left ventricu-
lar function, was improvement of coronary perfusion
and the prevention of early thrombosis in the im-
planted stent [9]. The application of catecholamine
along with IABP was not sufficient to control the
LOS symptoms.
In the patient described here, the index event
from which remodelling begins was the inferior
myocardial infarction in 1995. According to the
pathogenesis of cardiac insufficiency, the multiple
compensation mechanisms activating the adrener-
gic nervous system, the renin–angiotensin–aldos-
terone system and the cytokine system were aimed
at fast restoration of the cardiovascular system and
were to lead to the asymptomatic clinical course of
the first myocardial infarction. Compensation mech-
anism action was favourable in the short-term.
However, chronic activation of the plasmatic and
systemic compensation mechanisms led in time to
regional and global remodelling of the left ventri-
cle and a subsequent myocardial infarction caused
by damage and ischaemia as well as by successive
activation of the compensation mechanisms. This
resulted in massive damage to the left ventricle and
its extension and a drop in LVEF to 16% with an
acute clinical manifestation in the form of the car-
diogenic shock and subsequent LOS, giving rise to
serious circulatory insufficiency [14].
Figure 1. Diagram of the HeartMate XVE implantation.
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The factor which seems to be of crucial impor-
tance in determining the scope of left ventricle re-
modelling following the myocardial infarction is the
patency of the coronary artery responsible for the
infarction. In the patient with cardiogenic shock
described by us the patency of the LAD responsi-
ble for the myocardial infarction was restored in the
fifth hour of the infarction with implantation of the
anti-mitotic coronary stent. Simultaneously, the
critically stenosed LCx responsible for the inferior
myocardial infarction nine years previously was di-
lated with the implantation of the anti-mitotic cor-
onary stent. Despite restoring patency and the stent
implantation into two coronary arteries, block of the
platelet receptor Gp IIb/IIIa by intravenous abcixi-
mab and application of anti-aggregation treatment
with clopidogrel combined with aspirin, the patient
incurred LOS. In this case the risk factors for pro-
gression of disruption of left ventricular function
were the anterior localisation of the myocardial in-
farction, LVEF below 20% and extensive akinesis
covering the anteriolateral wall and the interven-
tricular septum.
Despite the restoration of LAD patency, arte-
rial flow was assessed as TIMI 2. Lack of efficient
flow in the coronary micro-circulation could be an
additional cause of cardiac muscle remodelling [15].
Currently applied pharmacotherapy with angi-
otensin convertase inhibitors and/or angiotensin II
receptor blockers, aldosterone antagonists and
b-adrenolytics is associated with a significant reduc-
tion in the morbidity and mortality of patients with
circulatory insufficiency and acts to stabilise and in
some cases to reverse the cardiac remodelling proc-
ess. Ramipril, aldacton, furosemide and digoxin
were applied in the case reported here. No b-adreno-
lytic drugs were successfully used for treatment of
acute cardiac insufficiency.
In some patients cardiac damage still ensues,
despite the application of drugs inhibiting the adren-
ergic system and the renin–angiotensin–aldoster-
one system. In the Royal Perth Hospital levosime-
nan was used, a drug which has an inotropic and va-
sodilatative action on the arteries, veins and coronary
vessels. Its application leads to a reduction in preload
and afterload, an increase in coronary flow and a po-
tential anti-arrhythmic effect as a result of opening
ATP-dependent potassium channels [16, 17]. Lev-
osimendan increases the sensitivity of Troponin C
to intracellular Ca2+ ions. Better contractibility of
the cardiac muscle cells is obtained by intensifica-
tion of the releasing factor for the contraction, with-
out changes in the total intercellular Ca2+ level, with
simultaneous reducion of preload and afterload.
Owing to an increase in sensitivity to Ca2+ ions heart
capacity increases, relaxation improves, and this
causes potential anti-arrthythmic action  and an anti-
stunning effect [18]. The lack of persistent improve-
ment in the objective haemodynamic parameters in
the 30 days after the myocardial infarction with the
maintained patency of both PCI-subjected arteries
was a reason for stating indications for OHTx and
the decision concerning LVAD implantation.
LVAD implantation is the most obvious exam-
ple of left ventricle remodelling reversal and is ex-
pressed in an increase in wall thickness and a de-
crease in left ventricle volume [19]. A study by Dipla
et al. [20] on the possibility of a potential reversal
of myocyte contractile defects by LVAD support
showed improvement of their contractility and de-
contractility compared to the defective myocytes
isolated from LVAD-unsupported hearts. A recently
published study by Mueller et al. [21] showed that
in 24% of mechanically supported patients sufficient
left ventricular function may be restored to allow
the LVAD to be disconnected. In the patient de-
scribed here CO before LVAD implantation was
4.5 l/min, CI: 2.1 l/min/m², PAWP: 30 mm Hg, systo-
lic pressure: 90 mm Hg, LVEF: 16%. Thus the de-
cision on LVAD implantation as a bridge to OHTx
was in this case based mainly on the clinical image
of the pharmacotherapy-resistant LOS, haemody-
namic criteria being treated as secondary.
HeartMate XVE, was used as a device for me-
chanical support of the left ventricle and may be
used both as a bridge for transplantation and as
a final therapy. In this device the inflow cannula is
fixed in the apex of the left ventricle and the out-
flow cannula is connected to the aorta. Blood from
the left ventricle flows into the device and is pumped
into the aorta. A small electrical engine serves as
a pump. Because of the special construction of the
device embolic and thrombotic incidents may, very
rarely, follow its implantation. As a result patients
do not require systemic anticoagulation [22]. Inflam-
matory complications (described in 30 ± 50% of the
total cases following HeartMate XVE implantation)
and embolic complications (rarely reported) that
were not life-threatening occurred in the patient
described here. Fast intervention with targeted
antibiotic therapy and the introduction of anti-
thrombosis treatment were possible owing to the
excellent co-operation between the patient and his
family and the medical team of the Advanced Heart
Failure and Cardiac Transplant Service. Staphylo-
coccus aureus MRSA and Citrobacter Koseri were
cultured from the LVAD cannula. The antibiotic
treatment included intravenous vancomycin and
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Figure 2. Patient P.T. with LVAD during physical exercise.
ticarcillin with clavulanic acid, intracardiac infusion
of flucloxacillin (through the PICC line, and oral
moxfloxacin 400 mg.
No post-surgery bleeding (which constitutes
a complication in approximately 50% of cases) was
observed in this patient, nor was there any devel-
opment of right ventricle insufficiency (observed in
20 ± 30% of cases following LVAD implantation).
However, microembolism into the central nervous
system occurred, which is rarely reported in this
group of patients. It should be noted that the war-
farin applied as anti-thrombosis treatment did not
cause the bleeding that frequently occurs in these
patients. The device itself does not require a pro-
longed application of oral anticoagulants. At present
patients with the implanted internal devices, Heart-
Mate or Novacor, may live outside hospitals in their
own homes awaiting heart transplant. In many cas-
es they can participate in social life, which increas-
es their quality of life greatly [2]. Because of the
limited number of donors and the long wait for
a heart transplant, ventricle supporting devices
have begun to play an increasing role in heart in-
sufficiency therapy, both as a bridge to OHTx and
as a final solution to decadent heart insufficiency.
They save the lives of patients whose condition is
not improved or stabilised by intravenous inotrop-
ic vasodilatative drugs, IABP support or mechani-
cal ventilation. The results of randomised assess-
ment of mechanical support in the treatment of
dilated cardiomyopathy (REMATCH) [23] suggest
an improvment in survival during the follow-up
period of over two years. In the case of the patient
described by us the device implantation resulted
in gradual haemodynamic improvement (CI:
3.17 l/min/m2, PAWP: 30 mm Hg), which was also
expressed by good tolerance towards b-blockers
(carvedilol, bisoprolol). This enabled the patient to
tolerate the waiting period of 13.5 months for the
OHTx, which was finally performed on 15th April
2005. While waiting for the heart transplant the
patient was able to lead an active life (Fig. 2).
Conclusions
1. Full coronary revascularisation with PCI meth-
od in extensive complicated myocardial infarction
further complicated by cardiogenic shock does
not always improve the haemodynamic status of
the patient in a satisfactory way, despite the ap-
plication of pharmacotherapy and IABP.
2. Levosimendan is a new inotropically positive
drug to be transiently applied in acute heart
failure during myocardial infarction.
3. Devices for internal mechanical support of
heart ventricles enable OHTx waiting time to
be extended while allowing the patient to main-
tain an active lifestyle.
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